sodium (5R)-6-{5H,6H,8H-imidazo[2,1-c][1,4]oxazin-3-ylmethylidene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate hydrate

• ChemBase ID: 154890
• Molecular Formular: C13H12N3NaO5S
• Molecular Mass: 345.30625
• Monoisotopic Mass: 345.03953578
• SMILES: c1c(n2c(n1)COCC2)/C=C/1\[C@@H]2N(C1=O)C(=CS2)C(=O)[O-].O.[Na+]
• Canonical SMILES: O=C1/C(=C/c2cnc3n2CCOC3)/[C@@H]2N1C(=CS2)C(=O)[O-].O.[Na+]
• InChI: InChI=1S/C13H11N3O4S.Na.H2O/c17-11-8(12-16(11)9(6-21-12)13(18)19)3-7-4-14-10-5-20-2-1-15(7)10;;/h3-4,6,12H,1-2,5H2,(H,18,19);;1H2/q;+1;/p-1/t12-;;/m1../s1
• InChIKey: UAZCFKAYAYJPDM-CURYUGHLSA-M

NAMES AND DATABASE IDS

Names

• IUPAC name: sodium (5R)-6-{5H,6H,8H-imidazo[2,1-c][1,4]oxazin-3-ylmethylidene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate hydrate
• IUPAC Traditional name: sodium (5R)-6-{5H,6H,8H-imidazo[2,1-c][1,4]oxazin-3-ylmethylidene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate hydrate
• Synonyms: 6-[(5,6-Dihydro-8H-imidazo[2,1-c][1,4]oxazin-2-yl)methylene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt hydrate; WAY-185489; BLI-489 hydrate

Database IDs

• CAS Number: 623564-40-9(anhydrous)
• MDL Number: MFCD22374169
• PubChem SID: 162249028
• PubChem CID: 71312021

CALCULATED PROPERTIES

• Acid pKa: 3.7518432
• H Acceptors: 5
• H Donor: 0
• LogD (pH = 5.5): -2.2635782
• LogD (pH = 7.4): -3.758194
• Log P: -2.0656204
• Molar Refractivity: 86.8934 cm^3
• Polarizability: 28.39123 Å^3
• Polar Surface Area: 87.49 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: H2O: >20 mg/mL
• Apperance: powder, yellow

Safety Information

• German water hazard class: 3
• Storage Temperature: room temp

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C13H10N3NaO4S · xH2O

DETAILS

Sigma Aldrich - PZ0022

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
BLI-489 is a penem β-lactamase inhibitor, which has shown activity against class A, C, and D β-lactamases. BLI-489 is being tested in combination therapy for drug-resistant bacteria.